Tequin (gatifloxacin) is an antibiotic used to treat bacterial infections in the lungs, in the sinuses and on the skin. It is also used to treat urinary tract infections, kidney infections and some sexually transmitted diseases. The Food and Drug Administration approved Tequin in 1999.
Tequin Linked to Diabetes and Blood-Sugar Problems
Studies have shown that Tequin could be associated with potentially fatal fluctuations of blood-sugar levels and severe cases of diabetes. Both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar) have been observed in patients taking Tequin. A Canadian study found that elderly patients taking the drug were four times more likely to develop hypoglycemia and 17 times more likely to develop hyperglycemia than patients taking other antibiotics.
In 2006, the FDA issued an alert warning of the potential dangers of Tequin in relation to hyperglycemia and hypoglycemia. In addition, the FDA issued a patient information sheet regarding the revised labeling for Tequin and new warnings and precautions associated with the drug.
To learn more about legal claims relating to Tequin, consult an attorney who practices in the area of drugs and medical devices.